论文部分内容阅读
65例晚期胃癌患者随机应用榄香烯乳氟脲嘧啶(EF方案,31例)与丝裂霉素氟脲嘧啶(MF方案,34例)进行同期治疗,有效率分别为32.3%(10/31),41.2%(14/34),两组间无显著差异(X~2＝0.55,P＞0.10)。EF方案毒副反应有恶心,呕吐100%(31/31),静脉炎及白细胞下降均为58.1%(18/31),发热19.4%(6/31),血小板减少仅3.2%(1/31)。研究表明,EF方案对晚期胃癌有较好疗效而血液学毒性较低,更适合于年老体弱及骨髓功能不良者的治疗。
Sixty-five patients with advanced gastric cancer were treated with eletesin fluorouracil (EF regimen, 31 cases) and mitomycin fluorouracil (MF regimen, 34 cases) at the same time with an effective rate of 32.3% (10/31). 41.2% (14/34), there was no significant difference between the two groups (X~2=0.55, P>0.10). The toxicity of EF regimen was nausea, vomiting was 100% (31/31), phlebitis and leukopenia were 58.1% (18/31), fever was 19.4% (6/31), and thrombocytopenia was only 3.2% (1/31 ). Studies have shown that the EF regimen has good curative effect on advanced gastric cancer with low hematological toxicity, and is more suitable for the treatment of frail elderly and patients with bone marrow dysfunction.